Philadelphia is one of America’s oldest and most productive biomedical research ecosystems, anchored by the University of Pennsylvania, Children’s Hospital of Philadelphia, and a deep bench of pharma R&D. Melan works with pharma, biotech, and academic medical teams across the Philadelphia region to structure drug discovery and translational research partnerships.
The Philadelphia Research Partnership Landscape
The University of Pennsylvania is a top-10 research university with over $1.9 billion in annual research expenditures. Penn’s Perelman School of Medicine is one of the most NIH-funded medical schools in the country, with particular strength in gene therapy, immuno-oncology, and neuroscience. The Children’s Hospital of Philadelphia Research Institute is the largest pediatric research center in the US. Thomas Jefferson University, Temple University, and Drexel University add significant biomedical and health services research capacity.
Philadelphia’s pharma heritage is deep. Johnson & Johnson operates major R&D in the region, GSK has a significant presence, and the Wistar Institute is a pioneer in vaccine research. The Penn Medicine-University City Science Center corridor houses hundreds of early-stage biotechs. The Pennovation Center and uCity Square represent a new wave of purpose-built innovation infrastructure. Spark Therapeutics, a Penn spinout, demonstrated the region’s capacity to translate academic gene therapy research into FDA-approved products.
Philadelphia’s partnership complexity comes from the density and diversity of its biomedical institutions — each with its own TTO processes, clinical trial infrastructure, and IP policies. Melan navigates this rich but fragmented ecosystem.
What Melan Does for Teams in Philadelphia
For pharma and biotech R&D teams: We identify academic and clinical partners across Penn, CHOP, Jefferson, and Wistar aligned with your therapeutic area priorities — from Penn’s leadership in CAR-T and gene editing to CHOP’s pediatric clinical trial infrastructure. We structure sponsored research agreements, licensing deals, and clinical collaboration frameworks.
For Penn and Philadelphia research institutions: We help TTOs and principal investigators find corporate partners who can advance their discoveries through clinical development, negotiate licensing terms that reflect the value of Penn’s foundational IP, and structure translational research partnerships.
For emerging biotechs: Philadelphia’s startup ecosystem benefits from Penn’s deep discovery pipeline. Melan helps early-stage companies establish academic licensing deals, structure sponsored research that supports their platform technology, and navigate the transition from university spinout to independent biotech.
FAQ
How does Melan help companies partner with Penn or CHOP?
We map the specific labs, clinical programs, and research centers aligned with your therapeutic priorities, then approach Penn’s Center for Technology Transfer or CHOP’s Office of Technology Transfer with a pre-structured partnership framework.
What makes Philadelphia unique for research partnerships?
Philadelphia combines one of the most NIH-funded academic medical centers in the country, the largest pediatric research center, a deep pharma R&D heritage, and the oldest biotechnology incubator in the US — all within a compact geography.
Does Melan work with Philadelphia gene therapy companies?
Yes. Penn’s Gene Therapy Program is one of the world’s leading academic gene therapy research centers. We help companies structure licensing and sponsored research agreements around AAV vectors, CAR-T platforms, and related technologies.
How do I start a research partnership in Philadelphia?
Contact Melan at themelan.com/contact-us. We discuss your R&D priorities and map the Philadelphia research ecosystem to identify the right collaborators.
Ready to form a research partnership in Philadelphia?
Melan helps pharma, biotech, and academic medical teams across Philadelphia structure drug discovery and translational research collaborations.
